Harmony Biosciences Preannounces Record Q2 Revenue of ~$261M, Reaffirms $1B+ Guidance, CFO Steps Down
HRMY sits 37% above its 52-week low of $25.52.
Summary
Harmony Biosciences preannounced record Q2 2026 WAKIX revenue of ~$261M (+30% YoY), reaffirmed full-year guidance of $1.0–$1.04B, and announced CFO Glenn Reicin is stepping down. Interim principal financial officer appointed from within.
Key Events · Earnings and Guidance · HRMY
-
Record Q2 Revenue Preannouncement
Driven by strong demand and commercial execution, preliminary Q2 2026 net product revenue for WAKIX reached approximately $261 million—a 30% year-over-year increase and a new quarterly record.
-
Full-Year Guidance Reaffirmed
Reflecting confidence in continued momentum through the second half, management reiterated 2026 net product revenue guidance of $1.0 billion to $1.04 billion.
-
CFO Departure
CFO Glenn Reicin stepped down effective July 16, 2026, to pursue other opportunities. The company stated the departure was not due to any disagreement on operations, policies, or practices.
-
Interim Financial Leadership Appointed
To ensure continuity in financial reporting and controls during the CFO search, Stephen Mollichella—SVP and Controller since 2021—was named Interim Principal Financial Officer.
Analysis · HRMY · Life Sciences
A record quarter and reaffirmed guidance underscore Harmony Biosciences' commercial strength, with WAKIX net revenue climbing 30% year-over-year to approximately $261 million. The company's confidence in hitting $1.0–$1.04 billion for the full year signals sustained momentum. Tempering the enthusiasm, however, is the departure of CFO Glenn Reicin—though the company stressed it was not due to any disagreement and quickly named an experienced internal controller as interim principal financial officer. The revenue beat and guidance reaffirmation are clear positives, but the CFO exit introduces leadership uncertainty, especially given recent insider selling by the former CFO. Full Q2 results are due August 4, 2026.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HRMY was trading at $34.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.